Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2176 participants.

Also called NCT02957682

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,176 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02957682
  • EudraCT 2016-003189-16
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Chile, Estonia, Japan, Mexico, Russia, South Africa, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02957682. Randomized; quadruple masking; primary purpose treatment. Start 2016-11-02 (actual); primary completion 2020-03-05 (actual). Results posted on 2021-05-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
Condition
Hypercholesterolemia
Intervention (Drug)
Praluent (Alirocumab)
Intervention (Drug)
Placebo
Lead sponsor
Regeneron Pharmaceuticals (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02957682
Content hash
ef7990a3330ca949e0f5f6123302beb6e0254f54e68096efb2c1d176c7f120cd